| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 22 | 2022 | 6975 | 1.470 |
Why?
|
| Platelet-Derived Growth Factor | 3 | 2022 | 617 | 1.260 |
Why?
|
| Colostrum | 4 | 2020 | 28 | 1.210 |
Why?
|
| Antigens, Neoplasm | 3 | 2024 | 1996 | 0.980 |
Why?
|
| Monocytes | 5 | 2020 | 2605 | 0.880 |
Why?
|
| Colonic Neoplasms | 9 | 2021 | 2541 | 0.770 |
Why?
|
| Immunoglobulins | 2 | 2018 | 855 | 0.720 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2022 | 1854 | 0.500 |
Why?
|
| T-Lymphocytes, Regulatory | 7 | 2022 | 3115 | 0.490 |
Why?
|
| Antibodies, Neoplasm | 2 | 2006 | 283 | 0.470 |
Why?
|
| Vascular Endothelial Growth Factor A | 6 | 2022 | 3517 | 0.440 |
Why?
|
| Cytokines | 10 | 2020 | 7452 | 0.430 |
Why?
|
| Glucagon-Like Peptide 2 | 1 | 2013 | 45 | 0.430 |
Why?
|
| Toll-Like Receptors | 1 | 2016 | 582 | 0.420 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2007 | 2956 | 0.380 |
Why?
|
| Neoplastic Stem Cells | 5 | 2021 | 1351 | 0.370 |
Why?
|
| Apoptosis | 13 | 2020 | 9527 | 0.360 |
Why?
|
| TOR Serine-Threonine Kinases | 5 | 2022 | 2062 | 0.360 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 1810 | 0.350 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 58 | 0.350 |
Why?
|
| Ureaplasma | 3 | 2019 | 59 | 0.340 |
Why?
|
| Heme Oxygenase-1 | 4 | 2015 | 365 | 0.340 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2009 | 1816 | 0.340 |
Why?
|
| Facial Neuralgia | 1 | 2009 | 10 | 0.330 |
Why?
|
| Graft Survival | 7 | 2015 | 3887 | 0.320 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 10266 | 0.290 |
Why?
|
| Complex Regional Pain Syndromes | 1 | 2009 | 122 | 0.290 |
Why?
|
| CA-19-9 Antigen | 1 | 2007 | 109 | 0.270 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2022 | 2885 | 0.270 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 4913 | 0.270 |
Why?
|
| Receptors, CXCR3 | 4 | 2012 | 240 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2022 | 2459 | 0.260 |
Why?
|
| Caco-2 Cells | 3 | 2022 | 367 | 0.250 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2007 | 338 | 0.250 |
Why?
|
| Clone Cells | 1 | 2009 | 1670 | 0.250 |
Why?
|
| Aspergillus fumigatus | 2 | 2018 | 158 | 0.240 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 2830 | 0.240 |
Why?
|
| Fibromyalgia | 1 | 2009 | 407 | 0.230 |
Why?
|
| Cholecalciferol | 2 | 2020 | 557 | 0.220 |
Why?
|
| Graft Rejection | 4 | 2012 | 4492 | 0.220 |
Why?
|
| Carcinogens | 3 | 2013 | 453 | 0.210 |
Why?
|
| Sirolimus | 7 | 2012 | 1540 | 0.210 |
Why?
|
| Kidney Neoplasms | 7 | 2015 | 4282 | 0.210 |
Why?
|
| Kidney Transplantation | 5 | 2012 | 4262 | 0.210 |
Why?
|
| Cell Proliferation | 12 | 2018 | 10478 | 0.210 |
Why?
|
| Neoplasm Transplantation | 7 | 2015 | 2014 | 0.200 |
Why?
|
| Immune Tolerance | 2 | 2009 | 2323 | 0.200 |
Why?
|
| Toll-Like Receptor 8 | 2 | 2015 | 98 | 0.200 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2022 | 178 | 0.200 |
Why?
|
| Cattle | 3 | 2018 | 3819 | 0.200 |
Why?
|
| Toll-Like Receptor 4 | 3 | 2017 | 588 | 0.200 |
Why?
|
| Animals | 38 | 2024 | 169285 | 0.200 |
Why?
|
| HT29 Cells | 5 | 2017 | 189 | 0.190 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2022 | 183 | 0.190 |
Why?
|
| Toll-Like Receptor 7 | 2 | 2015 | 169 | 0.190 |
Why?
|
| Ureaplasma urealyticum | 2 | 2019 | 39 | 0.190 |
Why?
|
| Pancreatic Neoplasms | 2 | 2016 | 5442 | 0.190 |
Why?
|
| Adenocarcinoma | 5 | 2021 | 6395 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 3 | 2016 | 9262 | 0.180 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2011 | 1105 | 0.180 |
Why?
|
| Tissue Donors | 1 | 2011 | 2381 | 0.180 |
Why?
|
| Epidermal Growth Factor | 2 | 2022 | 697 | 0.180 |
Why?
|
| Forkhead Transcription Factors | 6 | 2022 | 1625 | 0.180 |
Why?
|
| Lymphatic Metastasis | 6 | 2020 | 2914 | 0.180 |
Why?
|
| Rheum | 1 | 2020 | 2 | 0.180 |
Why?
|
| Mesenchymal Stem Cells | 2 | 2022 | 1673 | 0.180 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2022 | 368 | 0.180 |
Why?
|
| Th1 Cells | 3 | 2018 | 1042 | 0.180 |
Why?
|
| Animal Testing Alternatives | 1 | 2020 | 15 | 0.180 |
Why?
|
| Cell Line, Tumor | 14 | 2016 | 17142 | 0.180 |
Why?
|
| Fluoxetine | 2 | 2015 | 733 | 0.170 |
Why?
|
| Immunotherapy | 1 | 2016 | 4754 | 0.170 |
Why?
|
| Mucormycosis | 2 | 2018 | 102 | 0.170 |
Why?
|
| Cyclosporine | 3 | 2011 | 777 | 0.170 |
Why?
|
| Anti-Infective Agents | 1 | 2007 | 983 | 0.170 |
Why?
|
| Ureaplasma Infections | 1 | 2019 | 25 | 0.160 |
Why?
|
| Immunosuppressive Agents | 5 | 2020 | 4206 | 0.160 |
Why?
|
| Humans | 66 | 2024 | 768171 | 0.160 |
Why?
|
| Prognosis | 11 | 2021 | 30009 | 0.160 |
Why?
|
| Pericytes | 1 | 2022 | 299 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2018 | 8648 | 0.160 |
Why?
|
| Rhizomucor | 1 | 2018 | 3 | 0.160 |
Why?
|
| Genetic Engineering | 1 | 2024 | 936 | 0.160 |
Why?
|
| Rhizopus | 1 | 2018 | 21 | 0.160 |
Why?
|
| Signal Transduction | 10 | 2022 | 23648 | 0.160 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2010 | 952 | 0.150 |
Why?
|
| Diabetic Foot | 1 | 2022 | 383 | 0.150 |
Why?
|
| Cancer Vaccines | 1 | 2006 | 1040 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2011 | 4648 | 0.150 |
Why?
|
| Mice, Nude | 6 | 2010 | 3623 | 0.150 |
Why?
|
| Glucuronidase | 1 | 2019 | 205 | 0.150 |
Why?
|
| Toll-Like Receptor 2 | 2 | 2017 | 348 | 0.150 |
Why?
|
| Neoplasms | 4 | 2024 | 22371 | 0.150 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2020 | 1942 | 0.150 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2016 | 199 | 0.150 |
Why?
|
| Immunologic Factors | 1 | 2007 | 1596 | 0.150 |
Why?
|
| STAT3 Transcription Factor | 1 | 2022 | 874 | 0.140 |
Why?
|
| Mucorales | 1 | 2017 | 35 | 0.140 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2022 | 507 | 0.140 |
Why?
|
| Interferon-gamma | 4 | 2010 | 3161 | 0.140 |
Why?
|
| Chemokines, CC | 1 | 2018 | 286 | 0.140 |
Why?
|
| Mice, Inbred BALB C | 9 | 2015 | 6231 | 0.140 |
Why?
|
| Abdominal Wall | 1 | 2018 | 166 | 0.140 |
Why?
|
| Chemokines | 2 | 2012 | 963 | 0.140 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 13677 | 0.140 |
Why?
|
| Plant Extracts | 1 | 2020 | 499 | 0.140 |
Why?
|
| Precancerous Conditions | 2 | 2013 | 985 | 0.130 |
Why?
|
| Antibodies | 1 | 2024 | 2421 | 0.130 |
Why?
|
| Chorioamnionitis | 1 | 2017 | 156 | 0.130 |
Why?
|
| Aspergillosis | 1 | 2018 | 242 | 0.130 |
Why?
|
| Skin | 3 | 2020 | 4505 | 0.130 |
Why?
|
| Glycoproteins | 3 | 2021 | 2202 | 0.130 |
Why?
|
| Peptides | 4 | 2021 | 4354 | 0.130 |
Why?
|
| Rats, Wistar | 4 | 2018 | 1890 | 0.130 |
Why?
|
| Osteopontin | 1 | 2017 | 311 | 0.130 |
Why?
|
| Cell Movement | 4 | 2018 | 5213 | 0.130 |
Why?
|
| Phagocytes | 1 | 2017 | 294 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2024 | 2568 | 0.130 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2019 | 642 | 0.130 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2020 | 667 | 0.120 |
Why?
|
| Constipation | 1 | 2020 | 570 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2021 | 998 | 0.120 |
Why?
|
| Neovascularization, Physiologic | 1 | 2022 | 1370 | 0.120 |
Why?
|
| bcl-X Protein | 1 | 2016 | 412 | 0.120 |
Why?
|
| Recombinant Proteins | 1 | 2024 | 6512 | 0.120 |
Why?
|
| Adenosine Triphosphate | 2 | 2022 | 2004 | 0.120 |
Why?
|
| Mice, Inbred NOD | 6 | 2018 | 1837 | 0.120 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2018 | 634 | 0.120 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 1512 | 0.120 |
Why?
|
| Melanoma | 5 | 2014 | 5706 | 0.120 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 4 | 2010 | 306 | 0.110 |
Why?
|
| Dimethylhydrazines | 1 | 2013 | 12 | 0.110 |
Why?
|
| Lung Injury | 1 | 2019 | 433 | 0.110 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2009 | 748 | 0.110 |
Why?
|
| Dietary Supplements | 1 | 2007 | 3445 | 0.110 |
Why?
|
| Pancreatitis, Chronic | 1 | 2016 | 282 | 0.110 |
Why?
|
| Blotting, Western | 3 | 2016 | 5028 | 0.110 |
Why?
|
| Antigens, CD | 3 | 2021 | 4035 | 0.110 |
Why?
|
| Tissue Scaffolds | 2 | 2020 | 951 | 0.110 |
Why?
|
| Food Deprivation | 1 | 2013 | 114 | 0.110 |
Why?
|
| Isoantigens | 2 | 2022 | 562 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-raf | 2 | 2011 | 205 | 0.110 |
Why?
|
| Reflex Sympathetic Dystrophy | 1 | 2013 | 60 | 0.110 |
Why?
|
| Fungal Proteins | 1 | 2017 | 906 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 757 | 0.110 |
Why?
|
| RNA, Messenger | 8 | 2022 | 12801 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 2 | 2016 | 1495 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2015 | 3187 | 0.100 |
Why?
|
| Wound Healing | 3 | 2022 | 2815 | 0.100 |
Why?
|
| Integrin alpha2 | 1 | 2012 | 39 | 0.100 |
Why?
|
| Mice | 21 | 2022 | 82049 | 0.100 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2013 | 94 | 0.100 |
Why?
|
| Glycolysis | 1 | 2016 | 837 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 2474 | 0.100 |
Why?
|
| Keratin-20 | 2 | 2009 | 31 | 0.100 |
Why?
|
| Transplantation, Homologous | 6 | 2012 | 4834 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2012 | 2846 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2017 | 4355 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2018 | 1613 | 0.100 |
Why?
|
| Urinary Tract Infections | 1 | 2018 | 804 | 0.100 |
Why?
|
| Calcineurin | 2 | 2012 | 235 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 3 | 2013 | 1703 | 0.090 |
Why?
|
| Rats, Inbred Lew | 3 | 2009 | 1163 | 0.090 |
Why?
|
| Quality Control | 2 | 2020 | 836 | 0.090 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2011 | 1767 | 0.090 |
Why?
|
| Anticarcinogenic Agents | 1 | 2012 | 251 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2015 | 564 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2013 | 4585 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 1657 | 0.090 |
Why?
|
| Receptors, Death Domain | 1 | 2010 | 31 | 0.090 |
Why?
|
| Stromal Cells | 1 | 2016 | 1337 | 0.090 |
Why?
|
| Immunohistochemistry | 7 | 2020 | 11095 | 0.090 |
Why?
|
| Th2 Cells | 2 | 2006 | 1078 | 0.090 |
Why?
|
| Aged | 17 | 2020 | 171502 | 0.090 |
Why?
|
| Ureteral Neoplasms | 1 | 2011 | 107 | 0.090 |
Why?
|
| Down-Regulation | 3 | 2012 | 2939 | 0.090 |
Why?
|
| Collagen | 1 | 2018 | 2645 | 0.090 |
Why?
|
| Mice, SCID | 5 | 2015 | 2627 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2011 | 646 | 0.090 |
Why?
|
| Neoplasms, Experimental | 1 | 2015 | 1230 | 0.080 |
Why?
|
| Flow Cytometry | 5 | 2013 | 5902 | 0.080 |
Why?
|
| Female | 27 | 2021 | 397187 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 1942 | 0.080 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2010 | 200 | 0.080 |
Why?
|
| Growth Inhibitors | 1 | 2010 | 375 | 0.080 |
Why?
|
| Infant, Premature | 1 | 2019 | 2123 | 0.080 |
Why?
|
| Hyperthermia, Induced | 1 | 2013 | 416 | 0.080 |
Why?
|
| Imidazoles | 1 | 2015 | 1169 | 0.080 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2010 | 611 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2015 | 5341 | 0.080 |
Why?
|
| Cyclins | 1 | 2011 | 606 | 0.080 |
Why?
|
| Heat-Shock Proteins | 1 | 2013 | 797 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 2237 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 615 | 0.080 |
Why?
|
| Male | 26 | 2021 | 364731 | 0.080 |
Why?
|
| Fluorouracil | 2 | 2011 | 1652 | 0.080 |
Why?
|
| Cell Culture Techniques | 1 | 2016 | 1667 | 0.080 |
Why?
|
| Serotonin | 1 | 2013 | 1043 | 0.080 |
Why?
|
| Chronic Disease | 4 | 2020 | 9384 | 0.080 |
Why?
|
| Intra-Abdominal Fat | 1 | 2013 | 625 | 0.080 |
Why?
|
| HLA-DQ Antigens | 1 | 2008 | 190 | 0.080 |
Why?
|
| Liver Neoplasms | 3 | 2010 | 4363 | 0.080 |
Why?
|
| Colon | 2 | 2013 | 1801 | 0.080 |
Why?
|
| Cell Adhesion | 2 | 2012 | 3097 | 0.080 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2009 | 101 | 0.070 |
Why?
|
| Middle Aged | 17 | 2021 | 223487 | 0.070 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2009 | 189 | 0.070 |
Why?
|
| Dermis | 2 | 2022 | 203 | 0.070 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2011 | 663 | 0.070 |
Why?
|
| Intestinal Mucosa | 2 | 2016 | 3044 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 2 | 2022 | 2631 | 0.070 |
Why?
|
| Interleukin-23 | 1 | 2009 | 202 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2011 | 560 | 0.070 |
Why?
|
| Hospitals, University | 1 | 2009 | 570 | 0.070 |
Why?
|
| Creatinine | 2 | 2011 | 1918 | 0.070 |
Why?
|
| Graft vs Host Disease | 1 | 2020 | 3049 | 0.070 |
Why?
|
| Fetal Blood | 3 | 2019 | 1361 | 0.070 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 2360 | 0.070 |
Why?
|
| Rats | 7 | 2018 | 23782 | 0.070 |
Why?
|
| Tacrolimus | 1 | 2011 | 750 | 0.070 |
Why?
|
| Neoplasm Proteins | 2 | 2011 | 3604 | 0.070 |
Why?
|
| Integrins | 1 | 2011 | 842 | 0.070 |
Why?
|
| Interleukin-10 | 2 | 2017 | 1184 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 4 | 2018 | 6124 | 0.070 |
Why?
|
| Dendritic Cells | 2 | 2017 | 2747 | 0.070 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2010 | 567 | 0.070 |
Why?
|
| Injections, Intravenous | 1 | 2009 | 1379 | 0.070 |
Why?
|
| Cell Cycle | 2 | 2012 | 2934 | 0.070 |
Why?
|
| Myocardium | 1 | 2019 | 4790 | 0.070 |
Why?
|
| Peritoneal Neoplasms | 1 | 2013 | 714 | 0.070 |
Why?
|
| Transplantation Tolerance | 3 | 2022 | 633 | 0.070 |
Why?
|
| Cells, Cultured | 5 | 2019 | 19025 | 0.070 |
Why?
|
| Models, Biological | 2 | 2020 | 9497 | 0.070 |
Why?
|
| Portal Vein | 1 | 2009 | 435 | 0.070 |
Why?
|
| HCT116 Cells | 2 | 2017 | 405 | 0.070 |
Why?
|
| Lipopolysaccharides | 3 | 2018 | 2222 | 0.060 |
Why?
|
| Cell Line | 2 | 2011 | 15602 | 0.060 |
Why?
|
| Disease Progression | 6 | 2013 | 13668 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2018 | 3612 | 0.060 |
Why?
|
| Neoplasm Staging | 4 | 2011 | 11244 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2012 | 5704 | 0.060 |
Why?
|
| Fibroblasts | 1 | 2016 | 4178 | 0.060 |
Why?
|
| Self Tolerance | 1 | 2006 | 122 | 0.060 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 2298 | 0.060 |
Why?
|
| GATA3 Transcription Factor | 1 | 2006 | 163 | 0.060 |
Why?
|
| Disease Models, Animal | 4 | 2010 | 18349 | 0.060 |
Why?
|
| Selectins | 1 | 2005 | 101 | 0.060 |
Why?
|
| Alternative Splicing | 2 | 2008 | 1105 | 0.060 |
Why?
|
| Epitope Mapping | 1 | 2006 | 301 | 0.060 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 420 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 2 | 2009 | 2004 | 0.060 |
Why?
|
| Immune System Diseases | 1 | 2007 | 253 | 0.060 |
Why?
|
| Prospective Studies | 5 | 2020 | 54924 | 0.060 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2011 | 794 | 0.060 |
Why?
|
| Autophagy | 1 | 2012 | 1351 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2010 | 4149 | 0.060 |
Why?
|
| Cell Hypoxia | 2 | 2017 | 662 | 0.060 |
Why?
|
| Transplantation, Heterologous | 2 | 2009 | 2393 | 0.050 |
Why?
|
| Fibrosis | 2 | 2022 | 2081 | 0.050 |
Why?
|
| Receptors, Chemokine | 1 | 2006 | 652 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2018 | 4543 | 0.050 |
Why?
|
| Interleukin-8 | 2 | 2017 | 705 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2010 | 6525 | 0.050 |
Why?
|
| Interleukin-17 | 1 | 2009 | 924 | 0.050 |
Why?
|
| Pain Measurement | 1 | 2013 | 3583 | 0.050 |
Why?
|
| Adult | 12 | 2020 | 223646 | 0.050 |
Why?
|
| Tissue Array Analysis | 2 | 2018 | 551 | 0.050 |
Why?
|
| Islets of Langerhans | 1 | 2008 | 1351 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2011 | 9419 | 0.050 |
Why?
|
| Immune System | 1 | 2007 | 800 | 0.050 |
Why?
|
| Coculture Techniques | 2 | 2016 | 1344 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 6082 | 0.050 |
Why?
|
| Cell Survival | 3 | 2017 | 5789 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 3728 | 0.050 |
Why?
|
| Histocompatibility Antigens | 1 | 2002 | 479 | 0.050 |
Why?
|
| Survival Analysis | 4 | 2019 | 10099 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2009 | 4034 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 11878 | 0.050 |
Why?
|
| Skin Neoplasms | 2 | 2011 | 5863 | 0.050 |
Why?
|
| Cell Transdifferentiation | 1 | 2022 | 186 | 0.050 |
Why?
|
| RNA, Small Interfering | 4 | 2011 | 3428 | 0.040 |
Why?
|
| Survival Rate | 3 | 2018 | 12840 | 0.040 |
Why?
|
| Heart Transplantation | 2 | 2015 | 3301 | 0.040 |
Why?
|
| Point Mutation | 1 | 2006 | 1596 | 0.040 |
Why?
|
| Goiter | 1 | 2020 | 86 | 0.040 |
Why?
|
| Inflammation | 2 | 2017 | 10873 | 0.040 |
Why?
|
| Interleukin-1beta | 2 | 2017 | 1028 | 0.040 |
Why?
|
| Bacteremia | 1 | 2007 | 985 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2011 | 3474 | 0.040 |
Why?
|
| Microarray Analysis | 2 | 2014 | 753 | 0.040 |
Why?
|
| Mice, Knockout | 4 | 2022 | 14488 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2008 | 11930 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2005 | 812 | 0.040 |
Why?
|
| Prostatic Neoplasms | 2 | 2012 | 11101 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2008 | 2575 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2011 | 2195 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2015 | 1169 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2005 | 2234 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2020 | 704 | 0.040 |
Why?
|
| Acute Disease | 1 | 2009 | 7243 | 0.040 |
Why?
|
| Protein Isoforms | 2 | 2017 | 1715 | 0.040 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2017 | 59 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 2057 | 0.040 |
Why?
|
| Infant, Newborn | 4 | 2019 | 26421 | 0.040 |
Why?
|
| Protein Transport | 2 | 2015 | 1951 | 0.040 |
Why?
|
| Spores, Fungal | 1 | 2017 | 90 | 0.040 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2017 | 260 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2020 | 549 | 0.030 |
Why?
|
| Intestine, Small | 1 | 2002 | 1217 | 0.030 |
Why?
|
| Lymphocytes | 2 | 2020 | 2614 | 0.030 |
Why?
|
| Rectum | 1 | 2021 | 900 | 0.030 |
Why?
|
| Nasopharynx | 1 | 2019 | 420 | 0.030 |
Why?
|
| Surgical Instruments | 1 | 2018 | 381 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2009 | 8741 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 2017 | 476 | 0.030 |
Why?
|
| Gene Expression | 3 | 2015 | 7601 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 10763 | 0.030 |
Why?
|
| Receptors, Interleukin-8A | 1 | 2014 | 47 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 2015 | 915 | 0.030 |
Why?
|
| G1 Phase | 1 | 2015 | 403 | 0.030 |
Why?
|
| Thyroid Gland | 1 | 2020 | 1171 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 3 | 2022 | 22380 | 0.030 |
Why?
|
| Ischemia | 1 | 2022 | 1900 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2020 | 65379 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2008 | 681 | 0.030 |
Why?
|
| Transfection | 2 | 2014 | 5756 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2013 | 411 | 0.030 |
Why?
|
| Lipid Peroxidation | 1 | 2013 | 276 | 0.030 |
Why?
|
| Lipectomy | 1 | 2013 | 114 | 0.020 |
Why?
|
| Protoporphyrins | 1 | 2012 | 169 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2018 | 1561 | 0.020 |
Why?
|
| Models, Animal | 1 | 2018 | 2122 | 0.020 |
Why?
|
| Tumor Escape | 1 | 2015 | 372 | 0.020 |
Why?
|
| Time Factors | 3 | 2013 | 40220 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2012 | 317 | 0.020 |
Why?
|
| Yugoslavia | 1 | 2011 | 23 | 0.020 |
Why?
|
| Benzenesulfonates | 1 | 2012 | 170 | 0.020 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2011 | 89 | 0.020 |
Why?
|
| Cystoscopy | 1 | 2011 | 128 | 0.020 |
Why?
|
| Toll-Like Receptor 10 | 1 | 2010 | 12 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 381 | 0.020 |
Why?
|
| Turkey | 1 | 2011 | 256 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2019 | 1682 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2011 | 257 | 0.020 |
Why?
|
| Transplantation | 1 | 2012 | 221 | 0.020 |
Why?
|
| Niacinamide | 1 | 2012 | 418 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2013 | 8542 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2012 | 6316 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 3620 | 0.020 |
Why?
|
| Cell Division | 2 | 2008 | 4477 | 0.020 |
Why?
|
| ras Proteins | 1 | 2015 | 1058 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2010 | 217 | 0.020 |
Why?
|
| Random Allocation | 1 | 2013 | 2395 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2012 | 531 | 0.020 |
Why?
|
| Germany | 1 | 2011 | 883 | 0.020 |
Why?
|
| Luciferases | 1 | 2010 | 713 | 0.020 |
Why?
|
| Valproic Acid | 1 | 2011 | 444 | 0.020 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2011 | 381 | 0.020 |
Why?
|
| Pyridines | 2 | 2012 | 2894 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2014 | 1530 | 0.020 |
Why?
|
| Purines | 1 | 2011 | 615 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2010 | 598 | 0.020 |
Why?
|
| Quality of Life | 1 | 2009 | 13490 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2014 | 1440 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2012 | 1074 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 59626 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2009 | 1769 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2012 | 1151 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2010 | 806 | 0.020 |
Why?
|
| Transplantation Immunology | 1 | 2008 | 537 | 0.020 |
Why?
|
| Kidney | 1 | 2022 | 7064 | 0.020 |
Why?
|
| Mutation | 2 | 2013 | 30237 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 1606 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2015 | 81760 | 0.020 |
Why?
|
| Leucovorin | 1 | 2008 | 643 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2020 | 12466 | 0.020 |
Why?
|
| Swine | 1 | 2016 | 5997 | 0.020 |
Why?
|
| Tissue Engineering | 1 | 2016 | 1893 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2010 | 1156 | 0.020 |
Why?
|
| Vitamin B Complex | 1 | 2008 | 299 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2018 | 4213 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2011 | 3590 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2008 | 640 | 0.020 |
Why?
|
| Phthalazines | 1 | 2008 | 397 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2006 | 311 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2011 | 1750 | 0.020 |
Why?
|
| Observer Variation | 1 | 2011 | 2621 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 1728 | 0.010 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 9540 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 2152 | 0.010 |
Why?
|
| Camptothecin | 1 | 2008 | 600 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 622 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2005 | 826 | 0.010 |
Why?
|
| Cell Differentiation | 2 | 2014 | 11677 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 5891 | 0.010 |
Why?
|
| Genes, ras | 1 | 2006 | 663 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2008 | 878 | 0.010 |
Why?
|
| Rats, Inbred WF | 1 | 2002 | 140 | 0.010 |
Why?
|
| Tumor Microenvironment | 1 | 2016 | 3948 | 0.010 |
Why?
|
| DNA Damage | 1 | 2012 | 2469 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2011 | 2885 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 2892 | 0.010 |
Why?
|
| Proteinuria | 1 | 2005 | 611 | 0.010 |
Why?
|
| Brain Death | 1 | 2005 | 359 | 0.010 |
Why?
|
| Child | 1 | 2009 | 80917 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 39354 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2018 | 22290 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 5797 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2011 | 2907 | 0.010 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2006 | 934 | 0.010 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2006 | 1099 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2006 | 21207 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 5505 | 0.010 |
Why?
|
| Recurrence | 1 | 2011 | 8509 | 0.010 |
Why?
|
| Immunization | 1 | 2002 | 1219 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 3740 | 0.010 |
Why?
|
| Liver | 1 | 2013 | 7578 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 7609 | 0.010 |
Why?
|
| Pregnancy | 1 | 2017 | 30255 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2018 | 41753 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2012 | 7876 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2006 | 5315 | 0.010 |
Why?
|
| Stem Cells | 1 | 2005 | 3538 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 16726 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 10397 | 0.010 |
Why?
|